A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas (RADIOCYST01)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02343692|
Recruitment Status : Unknown
Verified October 2019 by University College, London.
Recruitment status was: Recruiting
First Posted : January 22, 2015
Last Update Posted : October 2, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Up to 13.5% of patients that undergo a magnetic resonance imaging (MRI) scan of their abdomen without pancreatic symptoms are found to have an incidental pancreatic cyst, with the frequency increasing with age. In a post-mortem series, 25% of patients had a pancreatic cyst, of which 32% were potentially premalignant and 3% malignant. Premalignant cysts are currently either observed or removed surgically according to international guidelines. Observation is associated with significant anxiety for patients and a growing cost to the National Health Service, while surgery for this usually benign condition is associated with not insignificant morbidity and mortality. Premalignant pancreatic cysts may be indolent for a number of years before malignant transformation, creating a window of opportunity for minimally invasive intervention and cure. New early treatment options for premalignant tumours are urgently required. This study will evaluate the safety and efficacy of a novel minimally invasive technique for the treatment of pancreatic cystic tumours; endoscopic ultrasound guided radiofrequency ablation (EUSRFA).
If successful it will offer an alternative to long term observation or surgery for patients with this condition.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cyst||Procedure: EUS guided RFA of cystic tumours of the pancreas||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||97 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas (RADIOCYST01)|
|Actual Study Start Date :||March 2016|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||August 2020|
Experimental: Radiofrequency abalation
Intervention: Endoscopic Ultrasound (EUS) guided radiofrequency ablation (RFA) of cystic tumours of the pancreas
Device: An RFA generator (ERBE VIO 300D, Dolby medical products, Scotland)
Procedure: Delivery of sequential doses of electrical energy at 10W for a total of up to 4 minutes 30 seconds (3 x 90 second applications) to ablate the cystic lesion.
Ablation of cystic tumours of the pancreas
Procedure: EUS guided RFA of cystic tumours of the pancreas
Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
- Presence of pancreatic cyst [ Time Frame: One year ]To evaluate pancreatic cyst ablation at 12 months following EUSguided radiofrequency ablation therapy in patients with pre-diagnosed cystic tumours of the pancreas.
- Mortality [ Time Frame: One year ]
- Morbidity [ Time Frame: One year ]
- Progression following treatment [ Time Frame: One year ]
- Rate of surgical resection [ Time Frame: One year ]
- Local complication rate [ Time Frame: One year ]
- Evaluation of surrogate markers of response (Imaging (CT, MRI, EUS) and serum markers.) [ Time Frame: One year ]
- Preliminary health economics analysis from questionnaires and cost diaries (Self-completed EQ-5D-5L questionnaire and cost diary.) [ Time Frame: One year ]Self-completed EQ-5D-5L questionnaire and cost diary.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- A diagnosis of a pancreatic cystic tumour based on multidisciplinary review of imaging, for which further surveillance with non-invasive imaging is indicated.
- Pancreatic cystic tumour between 0.5 and 3cm in size. Cysts greater than 3cm or with mural nodules can be included only if patients are unsuitable for surgical resection.
- ECOG performance status 0, 1 or 2.
- Estimated life expectancy of at least 12 weeks.
- Age >18 years.
- Capable of giving written informed consent.
- Women of child-bearing potential must have a negative pregnancy test (qualitative serum hCG) in the week before treatment, AND be using an adequate contraception method, which must be continued for at least 1 week after RF.
- A diagnosis of a pancreatic cystic tumour where surgical resection is indicated.
- Pancreatic cysts greater than 3cm or less than 0.5cm in size.
- Benign pancreatic cysts (e.g. pseudocyst).
- Serous cystadenomas.
- Pancreatic cysts with malignant transformation.
- Cysts involving or in close proximity to vessels or the biliary tree where the zone of ablation is likely to compromise these structures.
- Cysts arising from the main pancreatic duct.
- History of active or prior malignancy that will interfere with the response evaluation (exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, nonmetastatic basal and/or squamous cell carcinomas of the skin, any early stage (stage l) malignancy adequately resected for cure greater than 5 years previously).
- Acute pancreatitis within the previous 4 weeks.
- Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial.
- Any psychiatric disorder making reliable informed consent impossible.
- Pregnancy or breast-feeding.
- ECOG performance status 3 or 4
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02343692
|Contact: Bina Shahfirstname.lastname@example.org|
|Contact: Chris Brew-Gravesemail@example.com|
|Royal Melbourne Hospital, Epworth Richmond||Recruiting|
|Contact: Andrew Metz|
|Principal Investigator: Andrew Metz, MBBS, FRACP|
|University Hospital Birmingham NHS FoundationTrust||Recruiting|
|Birmingham, United Kingdom, B15 2TH|
|Principal Investigator: Brinder Mahon, MD|
|Glasgow Royal Infirmary||Recruiting|
|Glasgow, United Kingdom|
|Principal Investigator: Lyn Smith, MD|
|Leeds Teaching Hospitals NHS Foundation Trust||Recruiting|
|Leeds, United Kingdom|
|Principal Investigator: Matthew Huggett, MD|
|University College London Hospitals NHS Foundation Trust||Recruiting|
|London, United Kingdom, NW1 2PG|
|Principal Investigator: Stephen P Periera, MB BS, FRCP|
|Royal Free London||Recruiting|
|London, United Kingdom, NW3 2QG|
|Principal Investigator: Stephen P Pereira, MB BS, FRCP|
|Imperial College Healthcare NHS Trust||Recruiting|
|London, United Kingdom, W2 1NY|
|Principal Investigator: Nagy Habib, MD|
|Barts Health NHS Trust||Not yet recruiting|
|London, United Kingdom|
|Principal Investigator: Patrick Wilson, MD|
|Homerton University Hospital NHS Foundation Trust||Recruiting|
|London, United Kingdom|
|Principal Investigator: Ray Shidrawi, MD|
|Kings College Hospital NHS Foundation Trust||Recruiting|
|London, United Kingdom|
|Principal Investigator: John Devlin, MD|
|Sub-Investigator: Mayur Kumar, MD|
|The London Clinic||Not yet recruiting|
|London, United Kingdom|
|Principal Investigator: Steve Pereira, MD|
|The Newcastle Upon Tyne Hospitals NHS Foundation Trust||Not yet recruiting|
|Newcastle-Upon-Tyne, United Kingdom, NE7 7DN|
|Principal Investigator: Kofi Oppong, MD|
|Nottingham University Hospitals NHS Trust||Recruiting|
|Nottingham, United Kingdom, NG7 2UH|
|Principal Investigator: Suresh Vasan Venkatachalapathy, MD|
|Principal Investigator:||Stephen P Pereira, MB BS, FRCP||Royal Free London|
|Responsible Party:||University College, London|
|Other Study ID Numbers:||
|First Posted:||January 22, 2015 Key Record Dates|
|Last Update Posted:||October 2, 2019|
|Last Verified:||October 2019|
Digestive System Diseases
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Endocrine System Diseases